长期的饮食限制对肝脏和外围胰岛素敏感性都有强烈的积极影响,以年龄和饮食依赖的方式
Joel C Fisher1, Aaffien C Reijne2, Kaja Hribar3
1Department of Biochemistry, Stellenbosch University, Stellenbosch, South Africa.
Aging cell
|November 11, 2025
概括
饮食限制 (DR) 可以提高小鼠的胰岛素敏感性,但其长期影响取决于饮食类型和年龄. 低脂肪饮食保持了益处,而高脂肪饮食随着时间的推移显示收益正在减少.
科学领域:
- 代谢和内分泌学
- 衰老研究研究 衰老研究
- 营养科学 营养科学
背景情况:
- 已知饮食限制 (DR) 可以改善胰岛素敏感性.
- 抗胰岛素的长期影响和饮食成分对胰岛素敏感性的影响仍未得到充分研究.
- 以前的研究还没有在慢性干预模型中广泛探索这些因素.
研究的目的:
- 研究饮食限制对胰岛素敏感性的长期影响.
- 为了确定饮食类型 (低脂肪与高脂肪-糖) 如何调节DR对胰岛素敏感性的影响.
- 评估衰老对DR诱导的代谢变化的影响.
主要方法:
- 从断奶到2岁,小鼠在自由选择 (AL) 或饮食限制 (DR) 条件下接受低脂肪 (LF) 或高脂肪糖 (HFS) 饮食.
- 使用 [6,6-2H2] 标记的葡萄糖进行口服葡萄糖耐受性测试,以评估葡萄糖代谢.
- 测量了血胰岛素度,肝脏和周围胰岛素敏感性.
主要成果:
- 与任意养相比,饮食限制显著降低了血胰岛素度.
- 在小鼠中,DR强烈提高了肝脏和外周胰岛素敏感性.
- 抗胰岛素对胰岛素敏感性的有益影响取决于饮食和年龄的影响,在LF组持续的好处和随着时间的推移在HFS组的影响减少.
结论:
- 长期的饮食限制有效地改善了胰岛素敏感性,但其有效性是由饮食组成和衰老所调节的.
- 低脂肪饮食与饮食限制相结合,似乎在整个衰老过程中提供了持续的代谢益处.
- 高脂肪糖饮食可能会减弱饮食限制对胰岛素敏感性的长期优势.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
665
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
665
Insulin: The Receptor and Signaling Pathways
2.7K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.7K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
244
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
244
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
171
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
171


